Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucokinase siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Glucokinase siRNA is a small interfering RNA designed to selectively knock down the expression of glucokinase (GCK), a key enzyme that acts as a glucose sensor and gatekeeper of glycolysis in the liver and pancreatic beta cells. In laboratory research, glucokinase siRNA is utilized as a tool to study the role of glucokinase in glucose sensing, glycolysis, lactate production, and the pathogenesis of metabolic disorders such as type 2 diabetes and obesity. By silencing GCK gene expression, researchers can evaluate the downstream metabolic effects of reduced glucokinase activity, such as decreased lactate secretion and altered glucose-regulated hormone release.
- Other names
- GCK siRNAglucokinase small interfering RNA
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)AGO2 (Argonaute RISC catalytic component 2)GSK3 (Glycogen synthase kinase 3 beta)RNA-sensing Pattern Recognition Receptors (Toll-like receptor 3, Toll-like receptor 7, Toll-like receptor 8, Retinoic acid-inducible gene I, and Melanoma differentiation-associated protein 5)GCK (Glucokinase)
Beyond the preview
Go deeper on glucokinase siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucokinase siRNA.